Jorjani Biomedicine Journal

en Midazolam enhances osteogenic differentiation of human bone marrow mesenchymal stem cells علوم پایه پزشکی Basic Medical Sciences تحقیقی Original article <div style="text-align: justify;">Background: Bone remodeling involves a balance between osteoblast-driven formation and osteoclast-mediated resorption, with disruptions leading to diseases like osteoporosis. Midazolam (MDZ), known for its sedative properties, has shown effects on cellular differentiation and hydroxyapatite formation in dental cells. However, its role in promoting osteogenic differentiation in human bone marrow mesenchymal stem cells (hBMSCs) remains unexplored, motivating this study to investigate its potential in bone regenerative therapies. Methods: Human bone marrow stem cells were cultured in the complete media with α-MEM, 10% FBS, and 1% pen/strep. Cell viability was determined with MTT assay in different concentrations of MDZ (0.125 to 1 µM) for 72 hours. Osteogenic differentiation was induced over 21 days using the selected doses of MDZ with osteogenic medium. The Alizarin Red S (ARS) staining was performed to determine the calcium deposit for osteoblast cells. Data were analyzed using repeated measure ANOVA, and a p-value <0.05 was considered statistically significant. Results: The MTT results for different concentrations of MDZ (0.125 to 1 µM) showed no significant cytotoxic effects on hBMSCs after 72 hours. Furthermore, ARS staining revealed increased calcium deposits in 0.5 µM MDZ compared to untreated and DMSO groups (P-Value =0.0001). These findings suggest that MDZ promotes mineralization at lower concentrations, highlighting its potential in osteogenic applications. Conclusion: Midazolam promotes osteogenic differentiation of hBMSCs, particularly at 0.5 µM concentration, without cytotoxic effects. These findings demonstrate that MDZ may be a potential compound for osteoblastogenesis; however, these findings require further in vivo studies to confirm the idea.  </div> Midazolam, Mesenchymal Stem Cells, Osteoblastogenesis 14 17 http://goums.ac.ir/jorjanijournal/browse.php?a_code=A-10-964-2&slc_lang=en&sid=1 Zeinab Mohammadi z.mohammadi@goums.ac.ir 100319475328460010583 100319475328460010583 No Metabolic Disorders Research Center, Biomedical Research Institute, Golestan University of Medical Sciences, Gorgan, Iran; Department of Clinical Biochemistry, School of Medicine, Golestan University of Medical Sciences, Gorgan, Iran Marie Saghaeian Jazi marie.saghaeian@goums.ac.ir 100319475328460010584 100319475328460010584 Yes Metabolic Disorders Research Center, Biomedical Research Institute, Golestan University of Medical Sciences, Gorgan, Iran; Stem Cell Research Center, Golestan University of Medical Sciences, Gorgan, Iran Seyyed Mehdi Jafari s.meh.jafari@goums.ac.ir 100319475328460010585 100319475328460010585 No Metabolic Disorders Research Center, Biomedical Research Institute, Golestan University of Medical Sciences, Gorgan, Iran; Department of Clinical Biochemistry, School of Medicine, Golestan University of Medical Sciences, Gorgan, Iran Seyed Mostafa Mir mostafamir1987@gmail.com 100319475328460010586 100319475328460010586 No Metabolic Disorders Research Center, Biomedical Research Institute, Golestan University of Medical Sciences, Gorgan, Iran; Department of Clinical Biochemistry, School of Medicine, Golestan University of Medical Sciences, Gorgan, Iran Massoud Amanlou amanlou@tums.ac.ir 100319475328460010587 100319475328460010587 No Department of Medicinal Chemistry, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran Jahanbakhsh Asadi ja_asadi@yahoo.com 100319475328460010588 0009-0004-8333-3026 No Metabolic Disorders Research Center, Biomedical Research Institute, Golestan University of Medical Sciences, Gorgan, Iran; Department of Clinical Biochemistry, School of Medicine, Golestan University of Medical Sciences, Gorgan, Iran